Statistics and outcomes
Since its inception, the PERT program has provided care for nearly 2,000 patients with PE blood clots. Because of our high patient volumes and collaborative team-based approach, we’ve been able to learn and make significant improvements in how we
evaluate and treat patients with PE blood clots.
One recent example is transitioning our first-line treatment strategy to catheter-directed (CD) therapies, where interventionalists use small catheters to suction out clots (thrombectomy) or dissolve clots by dripping small of clot-busting medications
(thrombolysis) over a period of time to reduce bleeding risk. Using these approaches at Beaumont has significantly reduces 30-day mortality, length of stay in the hospital, and major bleeding rates for those patients who are appropriate candidates
for CD therapies.
|Variable||Standard Anti-coagulation||CD Therapy||Percent Difference|
|Length of stay in hospital||7 days||4 days||42.9%|
|Major bleeding event||13%||3.3%||74.6%|
Because Beaumont offers 24/7 coverage by a multidisciplinary group of PE experts, we have become a transfer resource for PE patients from other hospitals. In 2017, Beaumont, Royal Oak received 27 transfers from other hospitals for patients with
PE, increasing to 92 transfer PE patients in 2019. This trend reflects of our commitment to program excellence, and our capacity to care for more critically ill patients.
Since launching the PERT program, Beaumont, Royal Oak has also increased the number of patients discharged on a direct oral anticoagulant (DOAC) instead of older blood thinner medications like warfarin (Coumadin) or enoxaparin (Lovenox). DOACs are known
to have significantly less interactions with food and medications, lower rate of bleeding events and are much easier to administer as they do not require routine blood work. Current practice far exceeds pre-PERT program data, where historical volumes
for discharging patient on a novel oral anticoagulant was below 30%.